French Trial Tragedy: Dosing Continued After Volunteer Hospitalized
This article was originally published in Scrip
Executive Summary
Data from the Phase I dose-escalation study of Bial's FAAH inhibitor BIA 10-2474 reveal that the first serious adverse reaction occurred on the fifth day after the daily dose had been increased from 20 mg to 50 mg in the multiple-dosing stage of the trial.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.